Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Cullinan Therapeutics (CGEM) EPS (Weighted Average and Diluted) (2021 - 2023)

Cullinan Therapeutics (CGEM) has 3 years of EPS (Weighted Average and Diluted) data on record, last reported at -$28.97 in Q4 2023.

  • For Q4 2023, EPS (Weighted Average and Diluted) fell 4895.79% year-over-year to -$28.97; the TTM value through Dec 2023 reached -$32.12, down 5439.0%, while the annual FY2024 figure was -$27.78, 13.51% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$28.97 in Q4 2023 per CGEM's latest filing, down from -$0.91 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $3.77 in Q2 2022 and bottomed at -$28.97 in Q4 2023.
  • Average EPS (Weighted Average and Diluted) over 3 years is -$2.89, with a median of -$0.73 recorded in 2022.
  • Peak YoY movement for EPS (Weighted Average and Diluted): soared 1079.55% in 2022, then plummeted 4895.79% in 2023.
  • A 3-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.79 in 2021, then rose by 26.97% to -$0.58 in 2022, then tumbled by 4895.79% to -$28.97 in 2023.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were -$28.97 in Q4 2023, -$0.91 in Q3 2023, and -$0.82 in Q2 2023.